DOI:

SR200 MyoCath™ percutaneous microimplant delivery system

Howard Leonhardt*, Richard Spencer

Description

The SR200 MyoCath™ is a endoventricular needle-injection catheter utilizing catheter tip deflection technology and a adjustable depth, spring-loaded needle to provide multiple and precise delivery of biologic injectate to targeted myocardium.

History

MyoCath™ intellectual property was secured in 1999 and 2000. Initial prototypes were created and design was finalized in 2000. Bench testing, design control testing, biocompatibility/toxicity testing, thrombogenicity testing, in vitro testing and in vivo testing were all completed in 2001. MyoCath™ is manufactured in an ISO certified, class 100,000 controlled environment room and has been in clinical use since 2002.

Technical specifications

Indication for use

MyoCath™ is an investigational device indicated for injecting an aqueous solution or suspension, for diagnostic or therapeutic purposes, into internal tissues or organs.

Tips and tricks for delivery (use)

– Use of a steerable guidewire is not required.

– Slight deflection of the catheter tip facilitates crossing the aortic valve when performing endoventricular injections.

– A 9F guide catheter can be used if additional back-up support is required to reach difficult areas (i.e. septal) of the left ventricle.

– During long procedures, flushing the catheter with cold saline restores torquability and back-up support.

– Using deliberate force to extend the needle and infusing the injectate slowly over several seconds helps to optimize channel creation and injectate retention in scarred areas of myocardium.

– PVCs and tactile feel will confirm presence of the needle against the myocardial wall.

– Mixing injectate with non-ionic contrast enhances visualization of injectate retention under fluoroscopy.

Preclinical experience

As part of the design validation effort, Bioheart, Inc. performed ten in vivo studies in the porcine model to assess performance and ease of use of the MyoCath™ in the hands of a number of experienced interventional cardiologists. The primary objective was to ensure the design is suitable for its intended use under simulated conditions in the animal model. Physicians rated the performance of the device using the following metrics:

– Device preparation

– Ease of access

– Ease of placement

– Needle core advancement / retraction

– Needle insertion / removal

– Device injection

– Device visualization

– Ease of removal

– Thrombogenicity

– Device integrity

– Overall performance

– Standard anticoagulation regime

– Comparison with standard practices

Overall, the physicians rated the MyoCath™ favorably and reported it performed in an acceptable manner.

Clinical experience

The MyoCath™ has been used in 25 clinical cases to-date. All clinical cases involved injections in chronically infracted left ventricles (septal, anterior and posterior locations were targeted). No adverse events related to MyoCath™ have ever been reported, and feedback captured from physicians following completion of these cases was highly positive.

Volume 1 Number 4
Feb 20, 2006
Volume 1 Number 4
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00027 Jul 7, 2025
Antithrombotic strategies after TAVI in light of cerebral microembolism
Dangas G and Nicolas J
free

Editorial

10.4244/EIJ-E-25-00028 Jul 7, 2025
The challenge of interpreting comparative TAVI studies
Rosseel L et al
free

Research Correspondence

10.4244/EIJ-D-24-01113 Jul 7, 2025
Restenosis patterns after percutaneous coronary intervention with drug-coated balloons for de novo coronary lesions
Matsuda K et al

Debate

10.4244/EIJ-E-25-00019 Jul 7, 2025
Colchicine benefits are overestimated and current recommendations are too strong: pros and cons
Bainey K and Rossello X

Expert Review

10.4244/EIJ-D-24-01003 Jul 7, 2025
Current and future applications of robotics in structural heart interventions
Chen X et al

Editorial

10.4244/EIJ-E-25-00024 Jul 7, 2025
The new balloon-expandable Myval transcatheter heart valve: only good news?
Pibarot P and Van Belle E
free
Trending articles
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
79.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
42

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved